

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Venkatesan *et al.*

Serial No.: 09/970,089

Filed: October 2, 2001

Title: Compounds for the Treatment of Autoimmune and Inflammatory Disorders

Assistant Commissioner for Patents
Washington, DC 20231

February 8, 2002

Transmittal of Information Disclosure Statement

Sir:


Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

RECEIVED

Respectfully submitted, APR 01 2002

TECH CENTER 1600/2900


Josephine Young
Reg. No. 48,308

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-2882 (Telephone)
404-572-5145 (Facsimile)




INFORMATION DISCLOSURE STATEMENT
Docket No. EMU 3020
09/970,089

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Josephine Young

Date: February 8, 2002